Resolution of Corticosteroid-Induced Diabetes in Allergic Bronchopulmonary Aspergillosis with Omalizumab Therapy: A Novel Approach

References

• Stevens D A, Moss R B, Kurup V P, and participants in the Cystic Fibrosis Foundation Consensus Conference, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: S225–264
   Web of Science ®Google Scholar
• El Dahr J M, Fink R, Selden R, Arruda L K, Platts-Mills T A, Heymann P W. Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 1513–1518
   PubMed Web of Science ®Google Scholar
• Leser C, Kauffman H F, Virchow C, Sr, Menz G. Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1992; 90: 589–599
   PubMed Web of Science ®Google Scholar
• Walsh T J, Anaissie E J, Denning D W, Herbrecht R, Kontoyiannis D P, Marr K A, Morrison V A, Segal B H, Steinbach W J, Stevens D A, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327
   PubMed Web of Science ®Google Scholar
• Paquot N, Schneiter P, Jequier E, Tappy L. Effects of glucocorticoids and sympathomimetic agents on basal and insulin-stimulated glucose metabolism. Clin Physiol 1995; 15: 231–240
   Google Scholar
• de Almeida M B, Bussamra M H, Rodrigues J C. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 2006; 7: 67–72
   PubMed Web of Science ®Google Scholar
• van der Ent C K, Hoekstra H, Rijkers G T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62: 276–277
   PubMed Web of Science ®Google Scholar
• Zirbes J M, Milla C E. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43: 607–610
   PubMed Web of Science ®Google Scholar
• Slavin R G, Gleich G J, Hutcheson P S, Kephart G M, Knutsen A P, Tsai C C. Localization of IgE to lung germinal lymphoid follicles in a patient with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1992; 90: 1006–1008
   Google Scholar
• Slavin R G, Bedrossian C W, Hutcheson P S, Pittman S, Salinas-Madrigal L, Tsai C C, Gleich G J. A pathologic study of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1988; 81: 718–725
   PubMed Web of Science ®Google Scholar
• Patterson R, Greenberger P A, Radin R C, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982; 96: 286–291
   PubMed Web of Science ®Google Scholar
• Greenberger P A. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110: 685–692
   PubMed Web of Science ®Google Scholar
• Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment. Respir Med 2004; 98: 915–923
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. Report of a WHO consultation. World Health Organization, Geneva 1999; 1–59
   Google Scholar
• Mathis A S, Liu M T, Adamson R T, Nambi S S, Patel A M. Retrospective analysis of early steroid-induced adverse reactions in kidney and kidney-pancreas transplant recipients. Transplant Proc 2007; 39: 199–201
   Google Scholar
• Yung B, Noormohamed F H, Kemp M, Hooper J, Lant A F, Hodson M E. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002; 19: 221–226
   PubMed Web of Science ®Google Scholar
• O'Riordan S M, Robinson P D, Donaghue K C, Moran A. Management of cystic fibrosis-related diabetes. ISPAD Clinical Practice Consensus. Pediatr Diabetes 2008; 28: 338–44
   Google Scholar
• Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43: 1249–1251
   PubMed Web of Science ®Google Scholar
• Holgate S T, Chuchalin A G, Hébert J, Lötvall J, Persson G B, Chung K F, Bousquet J, Kerstjens H A, Fox H, Thirlwell J, Cioppa G D. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–638
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491–498
   PubMed Web of Science ®Google Scholar